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The Western Pacific amyotrophic lat-
eral sclerosis and parkinsonism-dementia
complex (ALS-PDC) has been described
as a Rosetta Stone that bears the essential
clue to understanding the etiopathogenesis
of related neurodegenerative diseases. The
three clinical forms (ALS, atypical parkin-
sonism with dementia, and dementia
alone) have a single pathology (polypro-
teinopathy, notably tauopathy), just as the
Rosetta Stone is inscribed with three dis-
tinct scripts bearing a common message.
As recently discussed (Kisby and Spencer,
2011), studies of ALS-PDC in the three
geographically separate and genetically
distinct island populations (Chamorros on
Guam; Japanese in Honshu Island’s Kii
Peninsula; and Papuan New Guineans in
Irian Jaya, Indonesia) show:
• ALS-PDC is primarily if not exclu-
sively an environmental disease: no gene
mutations identified in related neu-
rodegenerative disorders are found in
Guam and Kii-Japan cases, and dis-
ease rates have steadily declined in the
three affected populations. Emigrants
from Guam may develop ALS-PDC
years or decades later, but disease
risk is absent in their offspring who
were born and live abroad. Conversely,
Filipino and other immigrants who
adopt the Chamorro lifestyle on Guam
may acquire the disease.
• As ALS-PDC declined during the twen-
tieth century, the disease changed its
clinical face from ALS in the first
third of life, to PD in the second,
and D in the third, a pattern consis-
tent with a dose-related response to
an environmental exposure that waned
with modernization. With this hypoth-
esis, those with the highest dose of the
putative environmental factor develop
fatal ALS (with sub-clinical nigrostriatal
damage) relatively shortly after expo-
sure; those with intermediate doses sur-
vive with amyotrophy long enough to
develop atypical parkinsonism; those
with low doses reach old age and display
dementia, while others with the lowest
exposure have subclinical neurofibril-
lary disease reminiscent of early aging.
Other features of ALS-PDC variably
include loss of olfaction, retinal pig-
ment epitheliopathy, and atypical skin
cytology.
• The most plausible but unproven trig-
ger decades before the disease sur-
faces in clinical form is exposure to
certain plant-derived neurotoxins in
food or medicine, or both. The raw
seed of the neurotoxic cycad plant
(Cycas spp.) was used to heal skin
lesions (Guam, Irian Jaya) and as a
tonic (Kii). On Guam, processed cycad
seed was a Chamorro staple, and the
cycad seed-eating flying fox (Pteropus
sp.) that bioaccumulates the cycad-
derived neurotoxin β-N-methylamino-
L-alanine (L-BMAA) was a delicacy.
• Among the many bioactive chemicals
in cycad seed, two with neurotoxic
properties are singled out as potential
triggers of ALS-PDC: (a) methy-
lazoxymethanol (MAM), a potent
genotoxin, carcinogen and develop-
mental neurotoxin that is stored in
the plant as an inactive β-glucoside,
the concentration of which in cycad
flour correlates significantly with
incidence rates for ALS and PD in
males and females on Guam, unlike
the concentration of (b) L-BMAA, a
weak excitotoxic amino acid that is
taken up by brain tissue and possibly
undergoes proteogenesis, resulting in
misfolded proteins; daily oral dosing
of macaques with L-BMAA for up to 3
months induces a L-dopa-responsive,
non-progressive motorsystem disor-
der with non-excitotoxic cortical and
spinal motor neuron pathology. Both
L-BMAA and MAM are metabolized to
formaldehyde, an established genotoxic
agent and human carcinogen.
Whereas, genotoxin-induced DNA dam-
age is rapidly repaired in non-nervous
tissue (i.e., cycling cells), this can persist
in the brain because some DNA-repair
mechanisms are weakly expressed in
post-mitotic cells. MAM-induces O6-
methylguanine (O6-mG) DNA damage,
promutagenic lesions that induce uncon-
trolled mitoses (tumorigenesis) in mouse
epithelial tissues and widespread degen-
eration in the developing murine brain.
O6-mG lesions are clearly responsible
for the MAM-induced neuronal loss
because the pathology is greater in mice
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FIGURE 1 | Proposed common pathway underlying cancer and neurodegenerative disease
that is mediated by DNA damage and epigenetic changes (modified from Spencer et al., 2012).
that lack the DNA-repair enzyme O6-
mG methyltransferase (Mgmt−/−) and
reduced or absent in mice that overexpress
MGMT (Kisby and Spencer, 2011). Motor
deficits in these mouse mutants are con-
sistent with the extent of DNA damage.
In sum, these findings suggest DNA dam-
age is an initial event that leads to brain
pathology (Figure 1).
MGMT activity is very low in the
young adult human brain and may be
absent in mature nerve cells. Mgmt−/−
mice, an animal model of the young adult
human brain, develop persistent brain
O6-mG DNA lesions following a single
dose of MAM. In the days following
MAM treatment, these DNA lesions mod-
ulate key brain cell-signaling pathways that
are also perturbed in human neurolog-
ical disease, notably Alzheimer’s disease,
Parkinson’s disease, and inherited and spo-
radic forms of ALS. Pathway analysis of
MAM-modulated genes that are anchored
to DNA damage reveals links with human
cancer, genetic disorders, and skin and hair
development (Kisby et al., 2011a). Several
of these cell-signaling pathways continued
to be modulated in the brain of Mgmt−/−
mice 6 months later, with de novo expres-
sion changes of numerous genes involving
olfaction (Kisby et al., 2011b).
These findings emphasize the relation-
ship between acquired brain tissue DNA
damage, modulation of cell-signaling
pathways, and the induction of early and
persistent molecular changes that lead
to neuronal demise. They also reveal
important relationships between seem-
ingly disparate diseases—cancer and
neurodegeneration—the phenotype of
MAM-induced DNA damage being deter-
mined, respectively, by the presence or
absence of the proliferative capacity
of target tissues. The genotoxic prop-
erties of MAM and formaldehyde, a
common metabolite of MAM and L-
BMAA, also involve non-coding RNAs
with functional roles in both neurodegen-
eration and cancer (Spencer et al., 2012)
(Figure 1).
While proof is lacking that cycad
toxin(s) trigger ALS-PDC, the results of
recent biochemical and systems biology
studies, coupled with the absence of
known mutations in related neurodegen-
erative disorders, encourage further efforts
to examine the molecular and cellular
actions of MAM and L-BMAA. These
studies not only highlight the response
of the brain to unrepaired DNA damage-
induced by a genotoxin (e.g., alkylat-
ing agent) as a potential initiator of
a neurodegenerative process, they also
provide a foundation for understanding
whether such effects can lead to persistent
changes at the protein level (e.g., tau and
synuclein), including the erroneous incor-
poration of foreign amino acids, a subject
of recent interest. The ability of MAM to
perturb synuclein and several other classes
of brain proteins (e.g., calcium homeosta-
sis, mitochondrial and RNA processing)
is consistent with this hypothesis (Kisby
et al., 2006).
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